纳米材料的基因毒性测试的监管实践和未来前景
Cristina Andreoli1, Maria Dusinska2, Cecilia Bossa1
1ISS - Environment and Health Department, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Regulatory toxicology and pharmacology : RTP
|June 7, 2025
概括
本综述审查了纳米材料 (NM) 的基因毒性测试,重点关注新方法方法 (NAM). 它强调需要协调,验证的NAM来改善NM风险评估和安全评估.
科学领域:
- 纳米毒理学研究
- 风险评估 风险评估
- 监管科学 监管科学
背景情况:
- 纳米材料 (NM) 的毒性与物理化学性质和细胞吸收有关.
- 现有的NM基因毒性标准化测试存在缺陷.
- 新方法 (NAM) 正在出现,以解决这些测试差距.
研究的目的:
- 通过监管领域对NMS进行当前的基因毒性测试方法进行审查.
- 探索NAM在克服NM风险评估挑战方面的潜力.
- 确定对NAM进行协调和验证的需要,以确保NAM的安全性.
主要方法:
- 批判性审查国际和欧盟关于NM遗传毒性测试的指导方针.
- 审查现有和新兴的新方法方法 (NAMs).
- 在纳米毒理学中分析人工智能和机器学习等技术进步.
主要成果:
- 目前的NM基因毒性测试面临着需要协调的挑战.
- 在下一代NM风险评估方面,NAM显示出前景.
- 进一步的研究,验证和合作对于NAM接受至关重要.
结论:
- 更广泛地接受NAMs需要监管机构,研究人员和工业之间加强合作.
- 标准化协议,明确的数据共享途径和国际合作是关键步骤.
- 像人工智能和机器学习这样的创新技术可以推进NM安全评估.
相关概念视频
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Drug Regulation
1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K


